ArQule, Inc.
All Topics
Find news about people
Find news on alumni of any org
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


Change Feed
ArQule, Inc.
... also previously served as Vice President, Chief Financial Officer and Treasurer of ArQule Inc. During his tenure at ArQule, he played an important role in ...
... therapy study. And Basilea bolstered its oncology pipeline with a deal for ArQule’s derazantinib. Back at Novartis, Jay Bradner questioned the wisdom of some of ...
... Deal-hungry Basilea has extended its cancer pipeline by licensing ArQule’s derazantinib, a phase 2-ready drug that slots in ahead of its in-house ...
... Basilea Pharmaceutica AG / Basilea licenses late-stage oncology drug candidate derazantinib from ArQule . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely ...
... ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational ...
... ECYT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), CASI Pharmaceuticals Inc. (NASDAQ: CASI), ArQule, Inc. (NASDAQ: ARQL) A technology category that is projected to be the biggest ...
... ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of ...
Subscribe now for full coverage on ArQule, Inc.
Start My Free Trial